A Phase I Open-Label, Multicenter, Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Trial Profile

A Phase I Open-Label, Multicenter, Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 06 Jun 2016 Number of treatment arms changed from 1 to 2.
    • 01 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 01 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top